Save time and jump to the most important pieces.
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
25-NSE - Redwoods Acquisition Corp. (0001907223) (Subject)
425 - Redwoods Acquisition Corp. (0001907223) (Subject)
8-K - Redwoods Acquisition Corp. (0001907223) (Filer)
NEW YORK, June 24, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or the "Company") announces the Company's common shares and warrants will begin trading on the NASDAQ Global Market under the ticker symbols "WENA" and "WENAW", respectively. ANEW is a specialty pharmaceutical company specializing in the advancement of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. Dr. Joseph Sinkule, Founder and CEO of ANEW, commented, "Today marks our first day as a publicly traded company and as a dedicated leader in the development of novel disease-modifying therapies for neurological and age-related disorders. We're a relatively new company but our manageme
ANEW MEDICAL, INC.'s shares and warrants are expected to begin trading on the Nasdaq Global Market under the tickers "WENA" and "WENAW", respectively. NEW YORK, NY, June 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company"), a biopharmaceutical technology company focused on developing disruptive new therapies to treat the central nervous system ("CNS") and neurodegenerative diseases, and Redwoods Acquisition Corp. (NASDAQ: RWOD) ("RWOD"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The combined company will be named "ANEW MEDICAL, INC." a
NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid